AEGiS-Reuters: Severe costs to Africa of HIV/AIDS predicted

Reuters, Ltd.Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
Click here to return to Reuters main menu


DonateNow


Severe costs to Africa of HIV/AIDS predicted

Reuters NewMedia - Tuesday September 19, 2000


PRAGUE (Reuters) - Southern Africa faces severe economic costs from the HIV/AIDS epidemic sweeping the region and will require international help to alleviate the problem, the International Monetary Fund said in its latest World Economic Outlook.

The costs, which some studies reckon will lead to a drop in annual economic growth rates of 1-2 percentage points, will exacerbate human suffering and social disruption and risk a vicious cycle of poverty and disease, the IMF said. "The HIV/AIDS problem in southern Africa is already of enormous dimension and...it is clear that these countries will require considerable external assistance to address it," the report said.

"To prevent the situation from deteriorating further, it will be critical to reduce the rate of new infections," the IMF said, citing some success in preventative measures in Uganda and Senegal.

The IMF said that by 2010 gross domestic product (GDP) per capita in the worst affected countries could be 5% lower than it would be without the effects of the disease.

It said even this number will underestimate the welfare cost because GDP per capita does not account fully for the human, social and pecuniary costs of HIV/AIDS.

"The epidemic creates a vicious cycle by reducing economic growth which leads to increased poverty which, in turn, facilitates the rapid spread of HIV/AIDS as household food and health spending declines thereby reducing resistance to opportunistic infections."

The disease affects all forms of the economy from the direct impact on the labor force to the effect on government budgets from the cost of additional healthcare to lower savings rates, the IMF said.
000919
RE000912


Copyright © 2000 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.   Contact Reuters.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .